STOCK TITAN
  1. Home
  2. Sec-filings
  3. PTCT
  4. [Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

Tax withholding share sales by PTC Therapeutics (PTCT) officer

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

PTC Therapeutics officer Neil Gregory Almstead reported automatic sales of company stock tied to restricted stock unit (RSU) vesting. On January 6, 2026, he sold 1,279 shares of common stock at $76.95 per share directly and 54 shares at $76.95 held indirectly through his spouse. On January 7, 2026, he sold an additional 1,026 shares at $77.48 directly and 52 shares at $77.48 through his spouse.

According to the footnotes, all of these sales were made under irrevocable “sell to cover” elections to satisfy tax withholding obligations arising from the vesting of RSUs granted in 2023 and 2025. Following these transactions, Almstead beneficially owns 116,077 shares directly and 6,850 shares indirectly through his spouse.

Positive

  • None.

Negative

  • None.

Insights

Routine tax-withholding sales from RSU vesting; limited signal.

The filing shows Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics, selling common stock on January 6–7, 2026. The transactions total several thousand shares at prices around $76.95 and $77.48, split between direct holdings and shares held indirectly "By Spouse."

Footnotes state that every sale was executed under an irrevocable "sell to cover" election to satisfy tax withholding from RSU vesting, including grants of 19,000 and 715 RSUs from January 3, 2025 and 17,000 and 710 RSUs from January 5, 2023. That framing indicates these are administrative, tax-driven dispositions rather than discretionary portfolio moves.

After the sales, Almstead still holds 116,077 shares directly and 6,850 indirectly, suggesting he retains a substantial equity stake. Given the tax-withholding context and continued ownership, a sophisticated investor would typically view this as routine compensation-related activity rather than a material change in outlook.

Insider Almstead Neil Gregory
Role CHIEF TECHNICAL OPS OFFICER
Sold 2,411 shs ($186K)
Type Security Shares Price Value
Sale Common Stock 1,026 $77.48 $79K
Sale Common Stock 52 $77.48 $4K
Sale Common Stock 1,279 $76.95 $98K
Sale Common Stock 54 $76.95 $4K
Holdings After Transaction: Common Stock — 116,077 shares (Direct); Common Stock — 6,850 shares (Indirect, By Spouse)
Footnotes (1)
  1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs from a January 3, 2025 grant of 19,000 RSUs. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 178 RSUs from a January 3, 2025 grant of 715 RSUs. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 177 RSUs from a January 5, 2023 grant of 710 RSUs.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Almstead Neil Gregory
(Last) (First) (Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE
(Street)
WARREN NJ 07059
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF TECHNICAL OPS OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/06/2026 S 1,279(1) D $76.95 117,103 D
Common Stock 01/06/2026 S 54(2) D $76.95 6,902 I By Spouse
Common Stock 01/07/2026 S 1,026(3) D $77.48 116,077 D
Common Stock 01/07/2026 S 52(4) D $77.48 6,850 I By Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs from a January 3, 2025 grant of 19,000 RSUs.
2. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 178 RSUs from a January 3, 2025 grant of 715 RSUs.
3. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs.
4. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 177 RSUs from a January 5, 2023 grant of 710 RSUs.
/s/ Avraham S. Adler, Attorney-in-Fact 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did PTC Therapeutics (PTCT) report for Neil Gregory Almstead?

Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics, reported sales of company common stock on January 6 and 7, 2026, including both directly held shares and shares held indirectly through his spouse.

How many PTC Therapeutics shares did Almstead sell and at what prices?

On January 6, 2026, Almstead sold 1,279 shares of common stock at $76.95 per share directly and 54 shares at $76.95 indirectly through his spouse. On January 7, 2026, he sold 1,026 shares at $77.48 directly and 52 shares at $77.48 through his spouse.

Why were these PTC Therapeutics insider share sales made?

Each sale is described as shares automatically sold under an irrevocable sell to cover election to satisfy tax withholding obligations related to the vesting of RSUs granted in 2023 and 2025.

How many PTC Therapeutics shares does Almstead own after these transactions?

Following the reported transactions, Almstead beneficially owns 116,077 shares of PTC Therapeutics common stock directly and 6,850 shares indirectly through his spouse.

What equity awards are linked to the reported PTC Therapeutics share sales?

The footnotes link the sales to tax withholding for RSUs, including the vesting of 4,750 RSUs from a 19,000-RSU grant dated January 3, 2025, 178 RSUs from a 715-RSU grant dated the same day, and 4,250 and 177 RSUs from grants of 17,000 and 710 RSUs dated January 5, 2023.

How are Almstead’s spouse’s PTC Therapeutics shares treated in this Form 4?

The filing reports some transactions as indirect ownership "By Spouse," with 54 and 52 shares sold on the two days and 6,850 shares beneficially owned indirectly after the transactions.